- Home
- XBP vs ALGS Comparison
XBP vs ALGS Comparison
Compare XBP & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBP | ALGS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3M | 34.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XBP | ALGS |
|---|---|---|
| Price | $3.20 | $5.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $39.33 |
| AVG Volume (30 Days) | 26.0K | ★ 47.9K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.67 | 88.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $872,690,000.00 | $2,186,000.00 |
| Revenue This Year | $2.59 | $32.20 |
| Revenue Next Year | $5.75 | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $3.98 |
| 52 Week High | $8.55 | $13.69 |
Technical Indicators
Market Signals| Indicator | XBP | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 43.77 |
| Support Level | $2.10 | $4.81 |
| Resistance Level | $3.87 | $6.91 |
| Average True Range (ATR) | 0.28 | 0.43 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 42.48 | 38.51 |
Price Performance
Historical ComparisonAbout XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.